Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.
A VP-16-resistant subline was established from THP-1 human monocytic leukemia cells by subculturing in stepwise increasing concentrations of the drug. The resistant cells (THP-1/E) were capable of sustaining continuous growth in 1.0 microgram/ml VP-16. The 50% inhibition dose (IC50) was 1.4 micrograms/ml or a 35-fold of the parent cells. A more than 18-fold IC50 was also obtained with teniposide (VM-26). However, no substantial cross-resistance was observed with 5 other antineoplastic drugs, IC50 values being limited below several times of THP-1.
Saijo
Y
Y
Department of Internal Medicine, Tohoku University, Sendai.
Kumano
N
N
Suzuki
S
S
Koinumaru
S
S
Sugawara
S
S
Oizumi
K
K
Motomiya
M
M
D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004351:Drug Resistance; D005047:Etoposide / Q000494:pharmacology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
D005047:Etoposide